It has been added to the cart.

It has been added to the comparison table.

TFAP

for Cellbiology
Specification Assay :
97.0+% (HPLC)
Manufacturer :
FUJIFILM Wako Pure Chemical Corporation
Storage Condition :
Keep at -20 degrees C.
Molecular Formula :
C13H10F3N3O
Molecular Weight :
281.23
  • Structural Formula
  • Label
  • Packing
SDS
Comparison
Product Number
Package Size
Price
Inventory
Distributor
205-17381
Barcode No
4987481482470
10mg
List Price
230.00 USD

In stock in Japan

Document

SDS
Product Specification Sheet
Spectral Data
Certificate of Analysis
Calibration Certificate

Applications

Gastric ulcer formation test in rats

01140720_img01.png
a-d)Photographes of excised stomachs; a) vehicle, b) TFAP 300 mg/kg p.o., c) indomethacin 10 mg/kg p.o., d) enlarged illustration of part c, e) Gastric damage score.

TTFAP, IMN (indomethacin), and aspirin were administered at 300, 10, and 30 mg/kg, respectively; mean + SEM; n = 4/group; ** p < 0.01 versus vehicle.

Gastric damage score was calculated by measuring the lengths, and summing the values for each rat at 4 h after oral administration of each compound. Indomethacin and aspirin induced gastric ulcer formation at 10 and 30 mg/kg, respectively (white arrow in panels c and d), while TFAP did not induce gastric ulcer formation even at 300 mg/kg.

Data was provided by Dr. Hiroki Kakuta, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Analgesic effect test

01140720_img02.jpg
a) Acetic acid-induced writhing test in mice (mean +SEM, n=10-11/group) b) Formalin test in rat; ○: vehicle, ▲: indomethacin 30mg/kg p.o., ■: aspirin 30 mg/kg p.o., ●: TFAP 30 mg/kg p.o. (mean ±SEM, n=8/group). * p < 0.05, ** p < 0.01 versus vehicle.

After oral administration of each compound, acetic acid aqueous solution was intraperitoneally injected or formalin was injected into the plantar surface of the hind paw. Then, analgesic effect was evaluated by counting the number of writhes, bites, and licks and so on. The results indicate that TFAP has an analgesic effect.

Data was provided by Dr. Hiroki Kakuta, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

Chorioallantoic membrane (CAM) assay

01140720_img03.jpg
Mean +SEM, n=6/group, * p < 0.05 versus vehicle.

The angiogenesis activity of TFAP was evaluated by the assay of chick chorioallantoic membrane (CAM). TFAP inhibited CAM angiogenesis at 300 ng/CAM.

Data was provided by Dr. Hiroki Kakuta, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.

References

  1. Kakuta, H., Zheng, X., Oda, H., Harada, S., Sugimoto, Y., Sasaki, K., Tai, A. : J. Med. Chem., 51, 2400(2008).
  2. Wako JIHO, 77(1), 6(2009).

Overview / Applications

Outline This product is for research use only. Do not administer it to human.

Although cyclooxygenase-1 (COX-1) inhibition is thought to be a major mechanism of gastric damage by nonsteroidal anti-inflammatory drugs (NSAIDs), some COX-1-selective inhibitors exhibit strong analgesic effects without causing gastric damage. However, it is not clear whether their analgesic effects are attributable to COX-1-inhibitory activity or other bioactivities.

We have launched N-(5-amino-2-pyridinyl)-4-(trifluoromethyl)benzamide (TFAP), which has a structure clearly different from those of currently available COX-1-selective inhibitors, is a potent COX-1-selective inhibitor (COX-1 IC50 = 0.80 +/- 0.05 um, COX-2 IC50 = 210 +/- 10 um). TFAP causes little gastric damage in rats even at an oral dose of 300 mg/kg, though it has an analgesic effect at as low a dose as 10 mg/kg. This shows that COX-1-selective inhibitors can be analgesic agents without causing gastric damage.

Reference:
Kakuta, H., Xiaoxia Zheng, Oda, H., Harada, S., Sugimoto, Y., Sasaki, K. and Tai, A.: "Cyclooxygenase-1-Selective Inhibitors Are Attractive Candidates for Analgesics That Do Not Cause Gastric Damage. Design and in Vitro/in Vivo Evaluation of a Benzamide-Type Cyclooxygenase-1 Selective Inhibitor", J. Med. Chem., 51, 2400-11 (2008).

Precautions for Use Packed on inactive gas

Property

Appearance White - pale brown, crystals - powder

Manufacturer Information

Alias

  • N-(5-Amino-2-pyridinyl)-4-(trifluoromethyl)benzamide

For research use or further manufacturing use only. Not for use in diagnostic procedures.

Product content may differ from the actual image due to minor specification changes etc.

If the revision of product standards and packaging standards has been made, there is a case where the actual product specifications and images are different.

877-714-1920

Hours of Operation: 8:00 - 17:00 (EST)For other hours than the above, please contact us via the inquiry form.